The affinity of the extracellular domain of integrins for ligand is regulated by conformational changes signaled from the cytoplasm. Alternative types of conformational movement in the ligandbinding headpiece have been proposed. In one study, electron micrograph image averages of the headpiece of integrin aV␤3 show two different conformations. The open conformation of the headpiece is present when a ligand mimetic peptide is bound and differs from the closed conformation in the presence of an obtuse angle between the ␤3 subunit hybrid and I-like domains. We tested the hypothesis that opening of the hybrid-I-like domain interface increases ligand-binding affinity by mutationally introducing an N-glycosylation site into it. Both ␤3 and ␤1 integrin glycan wedge mutants exhibit constitutively high affinity for physiological ligands. The data uniquely support one model of integrin activation and suggest that movement at the interface with the hybrid domain pulls down the C-terminal helix of the I-like domain and activates its metal ion-dependent adhesion site, analogously to activation of the integrin I domain.
I
ntegrins are a family of Ϸ25 cell adhesion molecules that mediate cell-cell, cell-extracellular matrix, and cell-pathogen interactions and govern migration and anchorage of almost all kinds of cells. Integrins are noncovalently associated ␣␤ subunit heterodimers. Each subunit contains a large N-terminal extracellular domain, a transmembrane segment, and a cytoplasmic C-terminal tail. One unique aspect of integrin function is that the affinity for biological ligand can be up-regulated by a process termed inside-out signaling (1) . This is particularly important during activation of leukocytes and platelets, where integrins are converted to high-affinity receptors in Ͻ1 s. It has been suggested that this rapid affinity up-regulation is accomplished by a conformational change in integrin extracellular domains triggered by cytoplasmic signaling pathways after cellular activation.
Several alternative models for conformational change have been proposed. Crystal structures obtained of the extracellular domain of ␣V␤3 in Ca 2ϩ (2) or by subsequent soaking in Mn 2ϩ and a cyclic Arg-Gly-Asp (RGD) peptide (3) revealed an unexpected bent conformation, in which the headpiece is folded over and makes extensive contacts with the tailpiece (Fig. 1A) . Upon ligand binding, no change was seen at the interface between the I-like and hybrid domains, and only a slight rotation between the ␤-propeller and I-like domains and small movements within the I-like domain were seen. It was hypothesized that both the liganded and unliganded bent structures were in the active state (2, 3) . In contrast, NMR, negative stain electron microscopy (EM) with image averaging, ligand binding, physicochemical, and mutational studies show that the bent conformation is physiologic and has low ligand-binding affinity and that activation results in a switchblade-like opening to an extended conformation (4, 5) . Two extended conformers were seen that differed in whether there was an acute or obtuse angle between the I-like and hybrid domains, i.e., the closed (Fig. 1B) and open ( Fig. 1C) conformations of the headpiece, respectively (5) . The closed conformation of the headpiece resembles that seen in the ␣V␤3 crystal structure. Only the open conformation of the headpiece was seen when ligand was bound, suggesting that in the absence of crystal lattice contacts, ligand binding induced (i) a swing-out of the hybrid domain, and (ii) disruption of the headpiece-tailpiece interface in which the hybrid domain is prominent, leading to integrin extension (5) . Lower resolution rotary shadowing EM studies from another group led to a completely different conclusion, that binding of cyclic RGD peptide results in separation of the ␣ and ␤ subunits in the headpiece and that separation between the ␣-subunit ␤-propeller domain and the ␤-subunit I-like domain induces the high-affinity state (6, 7) . Based on the negative stain EM studies, we hypothesized that the opening of the angle between the I-like domain and the hybrid domain in ␤ subunit is the key feature of the high-affinity conformer. To mimic this conformation, we have introduced a glycan wedge at the domain interface and have successfully engineered ␣IIb␤3, ␣V␤3, and ␣5␤1 integrins that show constitutively high affinity. Furthermore, the results suggest that axial movement of the C-terminal helix of the ␤ subunit I-like domain is responsible for affinity modulation, suggesting the existence of a common theme for activation of all integrins.
Materials and Methods
Plasmid Construction, Expression, and Ligand-Binding Activity of Integrins on Chinese Hamster Ovary (CHO)-K1 Cells. Plasmids coding for full-length human ␣IIb, ␤3, and ␤1 were subcloned into pcDNA3.1͞Myc-His(ϩ) or pEF1͞V5-HisA, as described previously (5), and were introduced into the CHO-K1 cells by using calcium phosphate precipitation. After selecting the transfected cells in a medium containing 5 mg͞ml geneticin G418 for 1 week, the surviving cells were assessed for integrin expression by flow cytometry using antibody AP3 to human ␤3 (American Type Culture Collection) or antibody TS2͞16 to human ␤1 (8). The cells were then selected by fluorescence-activated cell sorting for expression of the desired level of ␣IIb␤3 or ␣5␤1 integrins. Binding of fluorescein-labeled human fibrinogen and ligand mimetic antibody PAC-1 (gift from Sanford Shattil, The Scripps Research Institute, La Jolla, CA) was performed as previously described (5) . For the binding of fibronectin fragment to human ␤1-expressing cells, the cells were incubated with 50 g͞ml biotinylated Fn 9 -10 (9) in the presence or absence of activating mAb TS2͞16 (10 g͞ml) at room temperature for 30 min and stained with FITC-streptavidin (Zymed) followed by flow cytometry. Cell adhesion to human fibrinogen (Enzyme Research Laboratories, South Bend, IN) was determined by assaying cellular phosphatase (10) .
Ligand-Induced Binding Site (LIBS) Expression. LIBS antibody AP5 was from the Fifth International Leukocyte Workshop (11) , and LIBS-1, LIBS-6, and PMI-1 antibodies were obtained from Mark H. Ginsberg (The Scripps Research Institute). CHO-K1 cells stably expressing wild-type or mutant ␣IIb␤3 were incubated with LIBS antibodies (10 g͞ml) at room temperature for 30 min, followed by staining with FITC-conjugated secondary antibody and flow cytometry.
Transient Transfection of 293T Cells. 293T cells were transiently transfected with wild-type or mutant integrin cDNAs by using calcium phosphate precipitation and were metabolically labeled with [ 35 S]cysteine͞methionine as described (5) . Labeled cell lysates were first immunoprecipitated with AP3 antibody, eluted with 0.5% SDS, and after the addition of 1% Nonidet P-40, were treated with or without 500 units of PNGase F (New England Biochemicals) at 37°C for 1 h. Material was subjected to nonreducing SDS͞7% PAGE and fluorography.
Results
Design of Constitutively Active Mutant Integrin. To test the hypothesis that opening the interface between the hybrid and I-like domains regulates integrin affinity for ligand, we mutationally introduced an N-glycosylation site in the ␣5-␤5 loop on the bottom of the I-like domain, where the angle with respect to the hybrid domain is most acute (Fig. 1 A) . This site is far from the ligand-binding site on the upper face of the I-like domain containing the metal ion-dependent adhesion site and thus should only enhance ligand binding allosterically. Furthermore, the site is distal from both the headpiece-tailpiece interface and the ␤-propeller-I-like domain interface (Fig. 1 A) and thus should not directly affect either of these interfaces, which have also been suggested to regulate ligand binding. The ␤3 mutation Asn-3053 Thr introduced the Asn-303-Ile-304 -Thr-305 Nglycosylation sequon and is predicted to result in attachment of a bulky N-glycan wedge at Asn-303.
The N-Glycan Wedge Mutant Has High Affinity for Ligand. Wild-type or mutant ␤3 (␤3 N305T ) was cotransfected with wild-type ␣IIb subunit into CHO-K1 cells. Stable clones expressing similar levels of mutant and wild-type ␣IIb␤3 were selected. Similar binding to wild-type and mutant receptors by mAbs to multiple ␣IIb and ␤3 epitopes including AP3 (anti-␤3), 7E3 (anti-␤3), HA5 (anti-␣IIb), and AP2 (anti-␣IIb␤3 complex specific) ( Fig.  2A) suggested that the mutant receptor adopts a native fold. Soluble ligand binding was measured by using two-color flow cytometry (5). Wild-type ␣IIb␤3 on CHO-K1 cells bound soluble fibrinogen and the ligand mimetic antibody PAC-1 only when stimulated by Mn 2ϩ and activating mAb PT25-2 ( Fig. 2 B and C) . In contrast, ␣IIb␤3
N305T
constitutively bound fibrinogen and PAC-1 antibody ( Fig. 2 B and C) . Binding by the mutant receptor in the presence of 5 mM Ca 2ϩ was comparable with that of wild-type receptor maximally activated with Mn 2ϩ and activating mAb and was not further increased by the addition of activating reagents. In contrast to the introduction of an N-glycosylation site, mutation of Asn-303 to Trp to introduce a bulky side chain (12) was not activating (data not shown), consistent with ample space for the Trp side chain in the closed interface. (2) is shown as a worm presentation. Note that the site of neoglycan introduction (Asn-303, gold CPK model) is located at the I-like domain͞hybrid domain boundary and faces away from the tailpiece-headpiece interface. A mutationally introduced disulfide bridge between residue 307 in ␣V and 563 in ␤3 that locks the overall bent conformation is shown as a yellow bond. Headpiece segments are color-coded as follows: ␣V ␤-propeller and thigh domains in magenta; ␤3 I-like domain in blue; and ␤3 hybrid domain in cyan. Tailpiece segments (i.e., calf-1 and calf-2 domains of ␣V, I-EGF3, I-EGF4, and ␤-tail domains of ␤3) are shown in gray. The figure was prepared by RIBBONS (27) . (B) The ␣V␤3 headpiece from the crystal structure. Each domain is color coded as in A. (C) Model of the high-affinity integrin headpiece. The hybrid domain of ␤3 (residues 55-107 and 352-434) was rotated Ϸ30°a way from ␣V subunit about residue 106 and submitted to the SWISS-MODEL server for refinement (28) . The GlcNAc2Man7 glycan chain (yellow) from human CD2 structure (1GYA) (29) was modeled into the inner side of the bend to simulate the glycan attachment at Asn-303. (B and C) CPK representations prepared with SWISSPDBVIEWER (30) .
The affinity state of ␣IIb␤3
was further tested in cell adhesion assays. Although high affinity is required for soluble ligand binding, basally active, i.e., low-affinity, ␣IIb␤3 can mediate cell adhesion to high-density substrates. Wild-type ␣IIb␤3 transfectants adhered to fibrinogen-coated surfaces at coating concentrations of Ն1 g͞ml (Fig. 2D) . Parent CHO-K1 cells showed no adhesion even at the highest concentration of fibrinogen (Fig. 2D) . In contrast, cells expressing ␣IIb␤3 N305T adhered to fibrinogen surfaces at coating concentrations as low as 10 ng͞ml (Fig. 2D) , demonstrating markedly augmented adhesiveness.
The Hyperactive Phenotype Is Due to the Introduced Glycan Chain. In 293T cell transient transfectants, the wedge mutant was hyperactive in soluble fibrinogen and PAC-1 binding assays just as in CHO-K1 cells (data not shown). Transiently transfected 293T cells were metabolically labeled, and ␣IIb␤3 complex was immunoprecipitated with ␤3 mAb AP3. Nonreducing SDS͞PAGE showed that the ␣IIb subunits migrated similarly, whereas the mutant ␤3 migrated slower than wild-type ␤3, with an Ϸ3-kDa increase in molecular mass (Fig. 3A, lanes 1 and 2) . Furthermore, this difference between wild-type and mutant ␤3 disappeared on deglycosylation by PNGase F (Fig. 3A, lanes 3 and 4) . The increased molecular mass of the mutant ␤3 is therefore due to additional N-glycosylation, suggesting that the N305T mutation resulted in the attachment of a glycan chain at Asn-303.
To confirm the causative role of Asn-303 glycosylation of ␤3 in ␣IIb␤3 activation, transient transfectants were treated before and after transfection with the N-glycosylation inhibitor tunicamycin. Ligand binding by wild-type ␣IIb␤3 was unaffected by tunicamycin, as treated and untreated cells showed similar fibrinogen binding after stimulation with Mn and activating mAb (Fig. 3B) . By contrast, tunicamycin treatment abolished the constitutive ligand-binding activity by ␣IIb␤3
, whereas like wild type it was still activatable by Mn and mAb (Fig. 3B) . Therefore, carbohydrate attachment at residue ␤3-Asn-303 endowed the receptor with high affinity rather than the mutation of Asn-305 to Thr.
Activation of ␣5␤1 with a Glycan Wedge. To generalize these findings, similar mutations were designed in the integrin ␤1 subunit. The equivalent mutation in the ␣5-␤5 loop, ␤1-Q312T, was not expressed well on the cell surface. Therefore, an N-linked site was introduced nearby in the ␣6-␤6 loop with the ␤1-P333N mutation, which introduced the sequon Asn-333-Lys-334 -Ser-335. This mutation was well expressed in stable CHO-K1 transfectants, in which human ␤1 associates with endogenous hamster ␣5 to make functional ␣5␤1 (13). Wild-type human ␤1 transfectants bound a biotinylated fibronectin fragment containing domains 9 and 10 (Fn 9 -10 ) only when the integrin was activated with mAb TS2͞16 to human ␤1 (Fig. 2E) . By contrast, ␤1 P333N transfectants bound Fn 9 -10 in the absence of mAb TS2͞16 activation (Fig. 2E) . Binding was mediated by transfected mutant human ␤1, as it was inhibited by anti-human ␤1 blocking mAb 13 (data not shown). Thus, a glycan wedge in the cleft between the I-like and hybrid domains can activate both ␤1 and ␤3 integrins.
The Glycan Wedge Favors the Extended Conformation of ␣IIb␤3.
Activation and͞or ligand binding change the conformation of ␣IIb␤3, resulting in the exposure of neo-epitopes called LIBS.
Such epitopes are buried in the bent conformation in headpiecetailpiece and ␣ tail-␤ tail interfaces and are exposed in the extended conformation (4). To probe the conformational state of the mutant ␣IIb␤3, binding of a panel of LIBS antibodies was determined. The mAbs AP5 (anti-␤3, residues 1-6), LIBS1 (anti-␤3), LIBS6 (anti-␤3, residues 602-690), and PMI-1 (anti␣IIb, residues 844-859) bound poorly to the cells stably expressing the wild-type ␣IIb␤3 in Ca 2ϩ but bound maximally when incubated with Mn 2ϩ and RGD peptide (14) (15) (16) (Fig. 4A Upper) . In contrast, all LIBS mAbs stained cells expressing the glycan wedge mutant ␣IIb␤3 brightly even in Ca 2ϩ in the absence of ligand, and no further increase was observed upon addition of Mn 2ϩ and RGD peptide (Fig. 4A Lower) . Another LIBS mAb D3 (anti-␤3, residues 422-490) also bound constitutively to the mutant ␣IIb␤3 (data not shown).
Wedged Integrin Locked in a Bent Conformation Shows High Affinity.
The hybrid domain is located in the headpiece and has a larger contribution than any other domain to the headpiece-tailpiece interface (5) . The glycan wedge is predicted not to push the hybrid domain toward the tailpiece, but laterally out of the headpiece-tailpiece interface, and thus to indirectly destabilize it. Ligand-induced swing-out of the hybrid domain has been previously predicted to destabilize the bent conformation by the same mechanism, and the maximal exposure of LIBS epitopes in the wedge mutant accords with this model of integrin activation (5) . The above studies did not define whether high ligandbinding affinity was a proximate effect of straightening the bend between the I-like and hybrid domains or secondary to transition from the bent to extended integrin conformation. The ␣V␤3 integrin can be locked in the bent conformation by introduction of an intersubunit disulfide bond between the ␣ subunit ␤-propeller domain and ␤ subunit I-EGF4 domain (Fig. 1 A) . The disulfide-locked integrin is inactive and resistant to activation by Mn 2ϩ and antibodies unless a disulfide-reducing agent is added (5) . The postulated lateral swing-out of the hybrid domain would not be blocked by this disulfide bond (Fig. 1 A) . Therefore, the two types of mutations were introduced into the same ␣V␤3 integrin molecules. Immunoprecipitation and nonreducing SDS͞PAGE confirmed complete formation of the disulfide bond between the ␣V head and ␤3 tail, suggesting that the doubly mutant receptor was locked in the overall bent conformation (Fig. 4B, lane 2) . This notion was further confirmed by the lack of binding by LIBS mAbs AP5, LIBS-1, LIBS-6, and D3 to ␣V G307C ␤3
N305T/S563C
, either in the presence or absence of RGD peptide (data not shown). Because we wanted to focus on conformational change within the ligand-binding site rather than on its accessibility, we used a small protein ligand, Fn 9 -10 , to minimize any influence of unbending on accessibility. The wedge mutation (N305T) constitutively activated the locked-bent receptor (i.e., ␣V G307C ␤3
S563C
) for binding to Fn 9 -10 , whereas locked-bent ␣V␤3 without the wedge mutation remained incapable of ligand binding even after the addition of activating mAb (Fig. 4C ). This result demonstrates that activation of highaffinity ligand binding by the wedge mutant is not secondary to adoption of the extended conformation of the integrin. When the larger ligand fibrinogen was used, however, the wedge-bent double mutant receptor did not show constitutively high activity (data not shown). This suggests that both the affinity of the ligand-binding site as well as its accessibility are important for binding of larger ligands.
Discussion
When liganded and unliganded receptors assume two distinct conformational states, it is generally possible to increase ligand affinity by stabilizing the liganded conformation because conformational change and ligand binding are thermodynamically linked (12, 17) . Our findings support the proposal that the change in angle between the I-like and hybrid domains in the transition between the open and closed headpiece conformations regulates ligand-binding affinity (5) . The findings do not support the proposal that the closed conformation of the headpiece is already in an active state and that no major interdomain conformational movements are associated with ligand binding (3). Our findings emphasize the importance of the angle between the ␤-subunit hybrid and I-like domains rather than separation between the ␣-subunit ␤-propeller and ␤-subunit I-like domains in integrin activation. Whereas our studies do not specifically address head separation, other results mitigate against it. The ␣ and ␤ subunits could not be distinguished from one another in EM studies that supported head separation (6), whereas higher resolution EM studies in which the ␣ and ␤ subunits could be distinguished showed no evidence for ligand-stimulated head separation (5), in agreement with many other EM studies (18) (19) (20) (21) . Furthermore, binding of cyclic RGD peptides stabilizes rather than destabilizes ␣ and ␤ subunit association (7, 22, 23) , and binding of the Arg moiety of RGD to the ␣ subunit and the Asp moiety to the ␤ subunit across the intersubunit interface would be destabilized by head separation.
The ␤-subunit I-like domain has a similar fold to the I domain, which is present in a subset of integrin ␣ subunits and serves as the major ligand-binding site in the integrins in which it is present. The I and I-like domains are each connected through both their N and C termini to the domains in which they are inserted, the ␣-subunit ␤-propeller and ␤-subunit hybrid domains, respectively. In the I domain, downward, axial displacement of the C-terminal ␣-helix causes rearrangement of residues that comprise the metal ion-dependent adhesion site, thereby increasing ligand affinity (24) . The structural similarity between I and I-like domains suggests a similar regulatory mechanism, in which a downward movement of the C-terminal ␣-helix of the I-like domain would allosterically regulate the conformation of the metal ion-dependent adhesion site and increase affinity for ligands. Indeed, the glycan wedge-induced widening of the angle between the I-like and hybrid domains is predicted to be tightly linked to downward displacement of the C-terminal ␣-helix of the I-like domain, based on the overall topology of the interdomain connections (Fig. 5) . Of the four secondary structural elements on either side of the two interdomain connections, three are internal ␤-sheet strands and hence are fixed in position by hydrogen bond networks. By contrast, the hydrogen bonds in an ␣-helix are all local, within the secondary structure element, and permit displacement relative to neighboring structural elements. Furthermore, the I-like domain ␣-helix connection to the hybrid domain ␤-sheet is the innermost connection, and a piston-like downward ␣-helix movement at this connection would result in swiveling about a fulcrum at the other connection, opening the interface to accommodate the nearby glycan wedge (Fig. 5) .
Ligand mimetic cyclic RGD peptides can bind to the lowaffinity, bent ␣V␤3 receptor with the closed interdomain angle as shown by the crystal structure (3). Because the conformational and ligand-binding equilibria are linked, and the bent conformation is favored in the absence of cyclic RGD peptide binding, whereas the extended, open conformation is favored when cyclic RGD peptide is bound and crystal lattice restraints are absent (5), it follows that the affinity of cyclic RGD peptide is higher for the extended open than the bent conformation of ␣V␤3. Ligand mimetics such as cyclic RGD peptides can be used at concentrations above their K D for the low-affinity state of the receptor and therefore can be used to drive integrin conformational change according to the law of mass action. By contrast, physiological integrin ligands are generally encountered at concentrations below the K D for the low-affinity state of the receptor; therefore, a change to a higher affinity conformation is usually required to drive ligand binding. Additionally, macromolecular ligands may lack access to the binding site in the bent integrin conformation. Physiologically, it is likely that integrins equilibrate between multiple conformational states rather than being locked in a specific conformation. Both signals within the cell that affect extracellular domain conformation and ligand binding will affect these equilibria. In this regard, active regulation of integrins on the cell surface is best described as moving the equilibrium point within a conformational spectrum, rather than turning a switch on and off.
Receptor conformational change, especially rearrangements involving interdomain movements (12, 25, 26) , is now gaining recognition as an important mechanism for controlling ligand binding. Thus, bulky amino acid side chain (12) and glycan wedges may have broad applications in designing mutant receptors with modified affinity. The present finding advances our knowledge of integrin activation at the molecular level. The successful application of the glycan wedge to ␤3 and ␤1 integrins implies that different integrins share the common principal of affinity modulation. The rational design of mutations that allosterically stabilize high-affinity or low-affinity conformations of integrins demonstrates marked advances in our understanding of the molecular basis of affinity regulation. This progress also holds out the promise that drugs might be designed that stabilize the low-affinity conformation of integrins, in contrast to the current generation of ligand-mimetic integrin antagonists that stabilize the high-affinity conformation.
